LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Regeneron Pharmaceuticals Inc

Fermé

SecteurSoins de santé

492.82 2.13

Résumé

Variation du prix de l'action

24h

Actuel

Min

491.18

Max

499.69

Chiffres clés

By Trading Economics

Revenu

-109M

809M

Ventes

-761M

3B

P/E

Moyenne du Secteur

12.47

51.198

BPA

8.22

Rendement du dividende

0.72

Marge bénéficiaire

26.701

Employés

15,158

EBITDA

-54M

1B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+46.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.72%

2.40%

Prochains Résultats

31 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-22B

53B

Ouverture précédente

490.69

Clôture précédente

492.82

Sentiment de l'Actualité

By Acuity

37%

63%

117 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 mai 2025, 11:55 UTC

Acquisitions, Fusions, Rachats

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million

29 avr. 2025, 11:07 UTC

Résultats

Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed

4 févr. 2025, 12:13 UTC

Résultats

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

5 juin 2025, 01:41 UTC

Acquisitions, Fusions, Rachats

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30 mai 2025, 08:58 UTC

Actions en Tendance

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 mai 2025, 08:56 UTC

Market Talk

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

19 mai 2025, 17:52 UTC

Actualités
Acquisitions, Fusions, Rachats

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19 mai 2025, 16:13 UTC

Acquisitions, Fusions, Rachats

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

19 mai 2025, 14:42 UTC

Actualités
Acquisitions, Fusions, Rachats

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19 mai 2025, 13:33 UTC

Actualités
Acquisitions, Fusions, Rachats

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- Update

19 mai 2025, 11:10 UTC

Acquisitions, Fusions, Rachats

Regeneron: To Ensure Compliance With 23andMe Consumer Privacy Policies, Applicable Laws on Customer Data >REGN

19 mai 2025, 11:10 UTC

Acquisitions, Fusions, Rachats

Regeneron: 23andMe Transaction Expected to Close in 3Q >REGN

19 mai 2025, 11:09 UTC

Acquisitions, Fusions, Rachats

Regeneron: To Continue All 23andMe Consumer Genome Services Uninterrupted >REGN

19 mai 2025, 11:08 UTC

Acquisitions, Fusions, Rachats

Regeneron: Named Successful Bidder in Bankruptcy Auction for Substantially All Assets of 23andMe >REGN

29 avr. 2025, 18:04 UTC

Market Talk
Résultats

Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

29 avr. 2025, 14:39 UTC

Market Talk
Résultats

Regeneron's Eylea Setback Drags Stock as Investor Frustrations Mount -- Market Talk

29 avr. 2025, 14:29 UTC

Résultats

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 avr. 2025, 13:11 UTC

Résultats

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 avr. 2025, 10:32 UTC

Résultats

Regeneron Pharma Cuts 2025 CapEx to $850M-$950M >REGN

29 avr. 2025, 10:30 UTC

Résultats

Regeneron Pharma 1Q Rev $3.03B >REGN

29 avr. 2025, 10:30 UTC

Résultats

Regeneron Pharma 1Q Net $808.7M >REGN

29 avr. 2025, 10:30 UTC

Résultats

Regeneron Pharma 1Q EPS $7.27 >REGN

29 avr. 2025, 10:30 UTC

Résultats

Regeneron Pharma 1Q Adj EPS $8.22 >REGN

22 avr. 2025, 10:51 UTC

Actualités

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28 févr. 2025, 12:00 UTC

Actualités

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 févr. 2025, 11:58 UTC

Résultats

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 févr. 2025, 11:37 UTC

Résultats

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 févr. 2025, 11:37 UTC

Résultats

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 févr. 2025, 11:36 UTC

Résultats

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 févr. 2025, 11:35 UTC

Résultats

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

Comparaison

Variation de prix

Regeneron Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

46.86% hausse

Prévisions sur 12 Mois

Moyen 724.35 USD  46.86%

Haut 900 USD

Bas 535 USD

Basé sur 23 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

23 ratings

17

Achat

5

Maintien

1

Vente

Score Technique

By Trading Central

542.44 / 599.76Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

117 / 380Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.